Stockreport

Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting

PORTOLA PHARMACEUTICALS  (PTLA) 
Last portola pharmaceuticals earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.portola.com
PDF – Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies –              – Also Accepted: Two Posters on Andexxa® and an Oral [Read more]